Journal
CURRENT MEDICINAL CHEMISTRY
Volume 13, Issue 16, Pages 1903-1913Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/092986706777585022
Keywords
Alzheimer disease; Prion diseases; transmissible spongiform encephalopathies; Creutzfeldt-Jakob disease; amyloid precursor protein; dementia; anti-amyloid therapies; protein-misfolding diseases
Ask authors/readers for more resources
Alzheimer disease (AD) and Creutzfeldt-Jakob disease (CJD) are sporadic and genetic neurodegenerative conditions characterized by brain accumulation and deposition of protein aggregates. In AD, the key pathogenic event is linked to the formation of a 4-kDa amyloid beta (A beta) peptide, generated by sequential cleavages of the amyloid precursor protein (APP). In CJD and other prion diseases, the process is initiated by conformational changes of the cellular prion protein, or PrPC, into a p-sheet rich isoform, named PrPSc, which acquires protease-resistance and detergent insolubility. Once generated, A beta and PrPSc are highly prone to misassembly under thermodynamically favourable oligomeric forms and protofibril/fibril structures. The variety of physicochemical states exhibited by A beta and PrPSc is accounted for by distinct molecular forms with different amino and/or carboxyl termini and alternative conformations. Unlike A beta, PrPSc is also infectious, and this feature poses public health concerns, as in the case of iatrogenic and variant CJD (vCJD). Several lines of evidence suggest that A beta and PrPSc are the main factors responsible for death of selected neuronal populations in brains of AD and prion disease's victims. Therefore, in addition to symptomatic treatment of dementia, therapeutic efforts are currently aimed at testing the efficacy of disease-modifying, anti-amyloid therapies. Experimental and clinical therapeutic interventions include passive and active immunization against amyloidogenic peptides, non immunological strategies, as well as drugs enhancing the nonamyloidogenic protein processing. In this review, we focus on molecular mechanisms of AD and prion diseases, and on novel treatment approaches.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available